ACP-autoantibody response in patients with early rheumatoid arthritis

ACP-autoantibody response in patients with early rheumatoid arthritis - AREPRA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00019198

Enrollment

200

Registered

2019-11-05

Start date

2019-11-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M05 M06

Interventions

Group 1: Exploratory, minimally invasive observational study to assess changes in autoantibodies and B cells in early RA (rheumatoid Arthritis). The intervention of the study is the Analysis in periph

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Early rheumatoid arthritis with the diagnosis made less than 2 years before inclusion

Exclusion criteria

Exclusion criteria: Prior therapy with rituximab or cyclophosphamide

Design outcomes

Primary

Measure	Time frame
The primary endpoint for this study is the change of ACPA (anti citrullinated protein antibodies) titers in the blood of early-stage rheumatoid arthritis patients 12 months after study entry.	—

Secondary

Measure	Time frame
Changes in ACPA-Isotypes, ACPA-subclasses and the B cell receptor repertoire in patients with early rheumatoid Arthritis 12 months after study entry.	—

Countries

Germany

Contacts

Public ContactJens Thiel

Department Innere Medizin Klinik für Rheumatologie und Klinische Immunologie

jens.thiel@uniklinik-freiburg.de004976127034210

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026